Men with prostate cancer are at higher risk of developing diabetes or diabetes risk factors if they receive androgen deprivation therapy (ADT) to block the production or action of male hormones that can fuel the growth of this cancer.
The study adds to the scientific evidence that ADT may increase the chance of diabetes.
The researchers compared 38 men with prostate cancer who received ADT and 36 men with less advanced prostate cancer who did not receive hormonal therapy.
Men in the ADT group had a twofold increased probability of having diabetes after ADT, compared with the non-ADT group, Rivera-Arkoncel reported.
According to the data, the prevalence of diabetes was 42 percent in the ADT group and 19 percent in the other group. In addition, the group receiving ADT had a higher prevalence of the metabolic syndrome than the non-ADT group did: 37 percent versus 28 percent, respectively.
“These patients may benefit from counseling, screening and closer monitoring for the development of these complications,” said the study’s lead author.
“An increased risk of diabetes with ADT has not previously been demonstrated in the Filipino population, which already has a high prevalence of diabetes,” she said.
She cautioned, however, that their cross sectional analytical study suggests, but cannot prove, that ADT is the cause of the increased prevalence of diabetes in men who received this hormonal therapy.